Lataa...
EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors
PURPOSE: Mutant selective irreversible pyrimidine based EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4791951/ https://ncbi.nlm.nih.gov/pubmed/25948633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2789 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|